Emory University Biocryst Pharmaceuticals Inc Transaction History

Emory University

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$1.59 - $3.45 $763,044 - $1.66 Million	-479,902 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $414,202 - $617,990	-165,681 Reduced 25.66%	479,902 $1.38 Million
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $1.11 Million - $3.48 Million	380,570 Added 143.6%	645,583 $2.45 Million
Q1 2019 May 09, 2019	SELL	$7.38 - $9.72 $389,162 - $512,555	-52,732 Reduced 16.6%	265,013 $2.16 Million
Q4 2018 Feb 12, 2019	BUY	$6.51 - $9.6 $2.07 Million - $3.05 Million	317,745 New	317,745 $2.56 Million

256

182M

839K

816K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.21B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Emory University, based on Form 13F filings with the SEC.

Stay updated on Emory University with notifications on news.